Amelioration of user experiences and glycaemic outcomes with an Advanced Hybrid Closed Loop System in a real-world clinical setting

• Published in: Diabetes research and clinical practice Vol. 178; p. 108986
• Main Authors: Beato-Víbora, Pilar Isabel, Gallego-Gamero, Fabiola, Ambrojo-López, Ana, Gil-Poch, Estela, Martín-Romo, Irene, Arroyo-Díez, Francisco Javier
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.08.2021
• Subjects: Advanced hybrid closed loop system; Patient satisfaction; Type 1 diabetes; Type 1 diabetes; Advanced hybrid closed loop system; Patient satisfaction
• ISSN: 0168-8227; 1872-8227; 1872-8227
• DOI: 10.1016/j.diabres.2021.108986

Automation in diabetes technology is rapidly evolving. The aim was to evaluate the real-world glycemic outcomes and user acceptance after 3 months of using the Medtronic 780G Advanced Hybrid Closed-Loop (AHCL) system. A prospective analysis was performed. A glucose target of 100 mg/dl and an active insulin time of 2 h were set. Capillary HbA1c, 2-week of pump and sensor data and several satisfaction questionnaire scores were compared at baseline and after 3 months of using the AHCL system. 52 subjects were selected (age: 43 ± 12 years, sex: 73% female, diabetes duration: 27 ± 11 years, higher education: 31%). Time in range (TIR) 70–180 mg/dl increased from 67.3 ± 13.6% to 80.1 ± 7.5% and time >180 mg/dl and >250 mg/dl were reduced (16.8 ± 8.4 vs 29.4 ± 15.1%, 2.7 ± 3.0% vs 6.9 ± 7.8%, respectively) (all p < 0.001), while time in hypoglycaemia remained below recommended targets. Time in Auto-Mode and sensor use were 94 ± 10% and 90 ± 11%, respectively. Auto-correction boluses represented 29 ± 12% of bolus insulin. Fear of hypoglycaemia, diabetes quality of life, sleep quality and satisfaction with the monitoring system improved after 3 months. The real-world use of the AHCL system Medtronic 780G provides an 80.1% TIR 70–180 mg/dl with minimal hypoglycaemia and an increased level of patient satisfaction.